Molecular Formula | C19H14F3N3O3 |
Molar Mass | 389.33 |
Density | 1.426±0.06 g/cm3(Predicted) |
Boling Point | 403.4±45.0 °C(Predicted) |
Solubility | DMSO : 36 mg/mL (92.47 mM) |
Appearance | powder |
Color | white to beige |
pKa | 11.41±0.70(Predicted) |
Storage Condition | 2-8°C |
In vitro study | T56-LIMKi efficiently inhibits the growth of ST88-14, U87, Panc-1 cells, A549 lung cancer cells with IC 50 values of 18.3, 7.4, 35.2 and 90 μM, respectively. T56-LIMKi decreases phosphorylated cofilin (p-cofilin) levels and thus inhibits growth of several cancerous cell lines, including those of pancreatic cancer, glioma and schwannoma. It blocks the phosphorylation of cofilin which leads to actin severance and inhibition of tumor cell migration, tumor cell growth, and anchorage-independent colony formation in soft agar. T56-LIMKi (10-50 μM) reduces p-cofilin in a dose-dependent manner in NF1 −/− MEFs with an IC 50 of 30 μM. Notably, the inhibitor does not affect the amounts of total cofil. 50μM T56-LIMKi causes a statistically significant reduction in the number of cells exhibiting stress fibers. |
In vivo study | T56-LIMKi can induce inhibition of cofilin phosphorylation and Panc-1 tumor shrinkage in vivo . Mice treated with T56-LIMKi (60 mg/kg) shows a significant decrease in tumor volume compared to control. |
UN IDs | UN 2811 6.1 / PGIII |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.569 ml | 12.843 ml | 25.685 ml |
5 mM | 0.514 ml | 2.569 ml | 5.137 ml |
10 mM | 0.257 ml | 1.284 ml | 2.569 ml |
5 mM | 0.051 ml | 0.257 ml | 0.514 ml |
biological activity | T56-LIMKi is a LIM kinase 2 (LIMK2) inhibitor that inhibits LIMK2-mediated phosphorylation of filamentous proteins. |
Target | Value |